DCGI sends notice to Serum India : Failure of trial reporting in UK

▴ DCGI sends notice to Serum India : Failure of trial reporting in UK
DCGI sends showcause notice to Serum India

The Drug Controller General of India (DCGI) has issued a notice to the Serum Institute for non-disclosure of information that the Oxford Covid vaccine trial has been discontinued in Britain. The participants in the vaccine trials discontinued the AstroZeneca Covid vaccine tests because they were ill. DCGI has issued a show cause notice to vaccine maker Serum Institute of India seeking clarification on this.

Some sources have confirmed that showcause has issued a notice to the DCGI for not disclosing the trial results that led to the illness of one of the participants in the UK trials of the AstraZeneca vaccine. The Serum Institute is an Indian manufacturer of the Covid vaccine, developed by the Jenner Institute of Oxford University in collaboration with the British-Swedish pharmaceutical company AstraZeneca.

The Oxford Covid vaccine is considered the most promising vaccine worldwide. In a notice to the Serum Institute, the DCGI questioned that "the Central Licensing Authority has not been informed about the withholding of clinical trials conducted by AstraZeneca in other countries."

The showcause notice questioned why the vaccine candidate should not be allowed to conduct Phase 2, 3 clinical trials in India until safety is established for the patients. Last month, the DCGI approved the Pune-based Serum Institute to conduct phase 2, 3 human clinical trials of the corona virus vaccine involving 1,000 people in 17 hospitals across the country.

Meanwhile, in the last 24 hours, India has scaled a new high of recoveries. The total number of recovered patients in a single day has surged to a record 74,894. With this, the total number of recoveries has touched 33,98,844 taking the Recovery Rate to 77.77%. The total number of recoveries on a weekly basis has increased from 1,53,118 during the third week of July to 4,84,068 in the first week of September 2020. A total of 89,706 new cases have been reported in the last 24 hours, of which Maharashtra has alone contributed more than 20,000 and Andhra Pradesh has contributed more than 10,000. 60% of the new cases are reported from only 5 States. The total number of active cases in the country stands at 8,97,394 as on date. Maharashtra is leading this tally with more than 2,40,000 whereas Karnataka and Andhra Pradesh follow with more than 96,000 each. Five States of Maharashtra, Karnataka, Andhra Pradesh, Uttar Pradesh and Tamil Nadu contribute 61% of the total active cases. A total of 1,115 deaths have been registered in the past 24 hours. Maharashtra has reported 380 deaths followed by Karnataka with 146 deaths, whereas Tamil Nadu has logged 87 deaths.

Tags : #DcgiNewsSep10 #AstraZenecaTrialHalted #SerumIndiaNoticeDcGI #OxfordCovidVaccineTrialPaused #LatestVaccineNewsSep10 #OxfordCovidVaccineNewsSep10 #LatestCovidNewsSep10 #LatestCovidVaccineNewsSep10

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024